CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CG Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$59.96+0.11 (+0.18%)
Close on Oct 19, 2026
- Market cap
- $5.29B
- P/E (TTM)
- –
- Dividend yield
- –
CG Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Commercial and Development Revenue | $5.45M | $4.30M | $3.23M | $1.51M | $0 | $0 | 87.5% | – |
| License and Collaboration Revenue | $778.00K | $768.00K | $806.00K | $666.00K | $551.00K | $1.14M | 12.5% | +41.2% |
By region
From the segment and revenue-disaggregation notes of CG Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.